News

Clinical Advisor18h

Cardiovascular Benefit Seen With Tirzepatide in Head-to-Head Trial

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.
GlobalData on MSN23h

Eli Lilly’s Mounjaro shows cardiovascular gains, but analysts underwhelmed

Eli Lilly’s trial evaluating Mounjaro in reducing cardiovascular risk met its endpoint, though missed analyst expectations.

Eli Lilly’s weight loss drug most effective at preventing heart attacks and strokes: What new study means for Mounjaro users

Trial shows that risk of a major adverse cardiovascular event is eight per cent lower in people on new therapy ...